In continuation of our Letter dated 08th August, 2026 we wish to inform you that a meeting oft he Board of Directors of the Company was held on Thursday, 13th August, 2026 at 03:00 pm ....

TEJNAKSH HEALTHCARE LIMITED Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060 Head Office : Institute of Urology Sakri Raod, Dhule - 424001 CIN : L85100MH2008PLC179034, E-mail : Instituteofurology@gmail.com Website : www.tejnaksh.com | Tel. No. 022-27454 2311, 02562 - 245322 / 245995 Date: 13-08-2026 BSE Limited PhirozeJeejeebhoy Towers, Dalal Street, ‘Mumbai — 400 001 Dear Sir/Madam, Serip Code: 539428 Sub: Outcome of- Board Meeting in accordance ‘with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 In continuation of our Letter dated 08" August, 2026 we wish to inform you that a meeting oft he Board of Directors of the Company was held on Thursday, 13 August, 2026 at Shop No 1 Building Name: Shivprasad Harihar Singh Compound, Block Sector: Jogeshwari East, Road: Caves Road. Pratap Nagar -Mumbai, Maharashtra, 400060 at 03:00 pm and has transacted the following: - 1. Considered and approved Un-Audited Financial Results (Standalone & Consolidated) for the quarter ended on 30™ June 2026 and took note of Limited Review Report thereon, in terms of Regulation.33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; : 2. The Board considered after due deliberation, resolved to reappoint Mr. Suhas Vasantrao Thorat (DIN: 09241231) as a Non-Executive Independent Director of the Company for a second term, pursuant to the provisions of Section 149(10) of the Companies Act, 2013 read with Schedule IV thereto and Regulation 25 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The reappointment shall be subject to approval of the shareholders at the General Meeting. A brief profile of Mr. Suhas Thorat is attached below and will be circulated to shareholders along with the notice of the General Meeting. - TEJNAKSH HEALTHCARE LIMITED Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060 Head Office : Institute of Urology Sakri Raod, Dhule - 424001 CIN : L85100MH2008PLC179034, E-mail : Instituteofurology@gmail.com Website : www.tejnaksh.com | Tel. No. 022-27454 2311, 02562 - 245322 / 245995 The meeting of Board of Directors commenced at 03:00 p.m. and concluded at ~ 6:30 p.m This is for your information and record. Thanking you. For Tejnaksh Healthcare Limited Ccal Dr. Ashish V. Rawandale -\5; 5 Managing Director DIN: - 02005733 - TEJNAKSH HEALTHCARE LIMITED Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060 Head Office : Institute of Urology Sakri Raod, Dhule - 424001 CIN : L85100MH2008PLC179034, E-mail : Instituteofurology@gmail.com Website : www.tejnaksh.com | Tel. No. 022-27454 2311, 02562 - 245322 / 245995 Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 relating to appointment of Directors of the Company: - Mr. Suhas Vasantrao Thorat: - Suhas Vasantrao Thorat, age 54 Years is an Undergraduate. He is having more than 15 years of experience as a Manager and rich Knowledge of supervising and coordinating the administration. He is professional with good experience of Managerial Skills and handling team. He possesses a diverse knowledge and wide range of experience in the Managerial field. . Further none of the existing directors or KMPs are related to Mr. Suhas Vasantrao Thorat. For, Tejnaksh Healthcare Limited -Dr. Ashish V. Rawandale Managing Director DIN: - 02005733 Maheshwari & Co. Chartered Accountants Independent Auditor’s Review Report on Unaudited Standalone Financial Results of Tejnaksh Healthcare Limited for the Quarter ended June 30, 2026 pursuant to the Regulation 33 of The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Review Report to, The Board of Directors Tejnaksh Healthcare Limited 1. We have reviewed the accompanying statement of unaudited standalone financial results of Tejnaksh Healthcare Limited (‘hereinafter referred to as ‘the Company’) for the quarter ended June 30, 2026 (the ‘Statement’), attached herewith, being submitted by the Company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the Regulations) 2. This Statement which is the responsibility of the Company's Management and has been approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 (‘the Act) as amended, read with relevant rules issued thereunder (‘Ind AS 34) and other recognized accounting principles generally accepted in India and is in compliance with the regulations. Our responsibility is to issue a report on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor oft he Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Attention is drawn to the fact that the figures for the three months ended March 31, 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end oft he third quarter of previous financial year had only been reviewed and not subjected to audit 5. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. For Maheshwari & Co. Chartered Accountants Firm’s Registration-No.: 105834W Membegrship No.: 172133 UDIN:26172133GMUTTI9461 Place: Mumbai Date: August 13, 2026 Office: 1302/1303, Solaris One, Vijay Nagar, Opp. Teli Gali, Andheri (East), 400069 Head office: 10-11, Third Floor, Esplanade Building, 3 A K Naik Marg, Near New Empire Cinema, Fort, CST, Mumbai 400 001 Tel.: +91-22-22077472/22072620, E-mail: vkasawa@maheshwariandco.in, Website: www.maheshwariandco.in TEJNAKSH HEALTHCARE LIMITED Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060 Head Office : Institute of Urology Sakri Raod, Dhule - 424001 CIN : L85100MH2008PLC179034, E-mail : Instituteofurology@gmail.com Website : www.tejnaksh.com | Tel. No. 022-27454 2311, 02562 - 245322 / 245995 TEJNAKSH HEALTHCARE LIMITED (CIN: L85100MH2008PLC179034) Statement of Standalone Financial Results for quarter ended June 30,2026 All amounts are [Showing first 8,000 characters — download PDF for full document]